Global In Vitro Diagnostic (IVD) Products Market Growth (Status and Outlook) 2025-2031

Global In Vitro Diagnostic (IVD) Products Market Growth (Status and Outlook) 2025-2031

The global In Vitro Diagnostic (IVD) Products market size is predicted to grow from US$ 81700 million in 2025 to US$ 105270 million in 2031; it is expected to grow at a CAGR of 4.3% from 2025 to 2031.

In Vitro Diagnostic (IVD) tests are a subset of medical devices. In vitro diagnostic products are those reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body.

In vitro diagnostics are tests that can detect diseases, conditions, or infections. Some tests are used in laboratory or other health professional settings and other tests are for consumers to use at home.

The global healthcare spending contributes to ca. 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The IVD market plays a significant role in the HC industry, influencing over 60% of laboratorial decision-making. However, it only accounts for ca. 2% of total HC spending, signifying an enormous potential for cost-effective tests.

The primary driver of growth in the IVD market is the aging of the global population. In addition, prevalence of chronic diseases is anticipated to propel this growth. More, growing demand for point-of-care devices and rapid diagnostic testing and increasing willingness to pay for preventive care testing.

COVID-19 pandemic is expected to continue to positively impact the market in 2020, 2021 and 2022, Due to the relaxation of global epidemic supervision, the reduction of COVID-19 testing in the post-epidemic era will reduce the total market size.

The In Vitro Diagnostics (IVD) market is driven by several key factors, including the rising prevalence of chronic and infectious diseases, advancements in diagnostic technologies, and increasing demand for personalized medicine. Innovations such as next-generation sequencing (NGS), point-of-care testing, and AI-driven diagnostics are transforming the industry by enabling faster, more accurate, and cost-effective testing. Additionally, the growing emphasis on preventive healthcare and the expansion of healthcare access in emerging markets are further fueling market growth. Regulatory support for precision diagnostics and increased investment in R&D also play a significant role in driving the adoption of IVD products globally.

Despite these drivers, the market faces several challenges. Stringent regulatory requirements and the high cost of R&D and clinical validation pose significant barriers for both established players and new entrants. Market saturation in developed regions and price sensitivity in emerging markets make it difficult to balance innovation with affordability. Furthermore, the integration of new diagnostic tools with existing laboratory infrastructure and IT systems can be complex and costly. Lastly, competition from established players and the need for significant capital investment to scale production and distribution add to the challenges for companies operating in this space.

The classification of In-Vitro Diagnostics (IVDs) Products includes Molecular Diagnostics, Immuno Diagnostics, Chemistry Diagnostics, POCT and Other. In 2023, POCT accounted for a share of 24.25% in the global In-Vitro Diagnostics (IVDs) Products market. In addition, this product segment is poised to reach US$ 29524 million by 2030 from US$ 19941 million in 2023.

North Americas is the largest consumption place, with a consumption market share nearly 38.19% in 2023. Following North Americas, APAC is the second largest consumption place with the consumption market share of 32.8%.

LPI (LP Information)' newest research report, the “In Vitro Diagnostic (IVD) Products Industry Forecast” looks at past sales and reviews total world In Vitro Diagnostic (IVD) Products sales in 2024, providing a comprehensive analysis by region and market sector of projected In Vitro Diagnostic (IVD) Products sales for 2025 through 2031. With In Vitro Diagnostic (IVD) Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Vitro Diagnostic (IVD) Products industry.

This Insight Report provides a comprehensive analysis of the global In Vitro Diagnostic (IVD) Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on In Vitro Diagnostic (IVD) Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global In Vitro Diagnostic (IVD) Products market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Vitro Diagnostic (IVD) Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Vitro Diagnostic (IVD) Products.

This report presents a comprehensive overview, market shares, and growth opportunities of In Vitro Diagnostic (IVD) Products market by product type, application, key players and key regions and countries.

Segmentation by Type:
Immuno Diagnostics
Chemistry Diagnostics
Molecular Diagnostics
POCT
Others

Segmentation by Application:
Hospital
Laboratory
Household
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Abbott
Danaher
Siemens Healthineers
Thermo Fisher Scientific
Sysmex
BioMerieux
QuidelOrtho
Becton Dickinson
Bio-Rad Laboratories
Hologic
LifeScan
Qiagen
Wuhan Easy Diagnosis
Wondfo
KHB
Hotgen
Mindray
Sinocare
Getein Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.